A 20-Year Experience

Background—The management of aortic intramural hematoma (IMH) involving the ascending aorta (type A) has not been well-established. The purpose of this study was to clarify the long-term clinical outcomes of patients with type A IMH who were treated with medical therapy and timely operation. Methods and Results—Clinical data including operative mortality, IMH-related events, and long-term survival were retrospectively reviewed in 66 patients with type A IMH, who were admitted to our institution from 1986 to 2006. Emergent surgical repair was performed in 16 (24%) patients because of severe complications, whereas 50 patients were treated with initial medical therapy. In medically treated patients, 15 (30%) patients who demonstrated progression to classic dissection or increase in hematoma size within 30 days underwent surgical repair except for 2 patients who refused surgery. The 30-day mortality rate was 6 % with emergent surgery and 4 % with supportive medial therapy. There were 7 late deaths and the actuarial survival rates of all patients were 963%, 943%, and 895 % at 1, 5, and 10 years, respectively. In medically treated patients, maximum aortic diameter was the only predictor of early and late progression of ascending IMH (hazard ratio, 4.43; 95 % CI, 2.04–9.64; P0.001). Aortic diameter 50 mm predicted progression of ascending IMH with the positive and negative value of 83 % and 84%, respectively. Conclusions—Combination of medical therapy and timely operation resulted in favorable long-term clinical outcomes in patients with type A IMH. (Circulation. 2009;120[suppl 1]:S292–S298.